NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen reported Q1 2026 financial results with a net loss of $1.7 million, significantly improved from $3.9 million in the prior year, aided by a $5.7 million non-cash gain on warrant derivatives. The company highlighted successful FDA alignment on the RESTORE registrational study for NVG-291 in chronic tetraplegia, with site activation underway and initiation targeted for mid-2026. Independent biomechanical gait analyses from the CONNECT SCI study are ongoing, with results expected in 2Q 2026 to differentiate neural recovery from compensatory movement.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- RESTORE study initiation on track for mid-2026; CONNECT SCI biomechanical gait analysis results anticipated in 2Q 2026; indication prioritization framework communication expected mid-2026
- Net loss
- 1700000
- Ga expenses
- 2700000
- Rd expenses
- 4900000
- Net loss yoy
- 3900000
- Cash and investments
- 16600000
- Unrealized gain warrants
- 5700000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.